Genomics

Genetic Risk Clinical Decision Support: Preparing Laboratory Results for Clinician Workflows

Physician reviewing a patient’s genetic risk result in the EHR

A precision-medicine laboratory can validate a polygenic, monogenic, or hybrid risk model; calculate scores at scale; stratify a population; and deliver a result to a referring provider.

None of that guarantees a clinician acts on it.

A primary-care clinician may see an elevated inherited cardiovascular-risk result during an annual visit and not know which next step applies. A cardiologist may see the same result in a patient already receiving preventive treatment and correctly take no new action. The result may travel as a PDF, remain in a portal, or reach the EHR as an attachment rather than as data that a downstream workflow can evaluate.

The score may be correct. The handoff may still be unengineered.

Direct answer

A genetic risk score can serve as an input to clinical decision support when the receiving workflow can interpret the result, assess its applicability to the patient, and combine it with relevant clinical context and governed decision logic. Structured, versioned delivery with clear model metadata and appropriate evidence provenance makes that use more dependable. A FHIR RiskAssessment may be an appropriate representation when it fits the receiving organization’s architecture. Delivering the result in FHIR does not, by itself, constitute clinical decision support, establish clinical utility, or guarantee clinician action.

A 2025 review in Nature Reviews Genetics found that clinical use of polygenic risk scores remains constrained by concerns about precision, transferability across diverse populations, provider and patient familiarity, reporting, workflow design, and clinical utility. The review also notes that risk scores are most credible when combined with conventional clinical risk factors and embedded in a defined pathway rather than delivered as stand-alone results. Clinical use of polygenic risk scores: current status, barriers and future directions

That integration burden does not begin at the health system. It begins at the laboratory that issues the result.

Engineer the risk-to-action handoff at the source.

NonStop builds the variant interpretation, evidence, reporting, and interoperability systems that let clinical genomics and precision-medicine laboratories deliver risk results as structured, action-ready data rather than static reports.

The Laboratory Owns the First Half of the Genetic Risk CDS Handoff

Genomic risk stratification can create a false impression of completion. A laboratory can validate a model, calculate scores, stratify a population, and issue reports. Every step can be technically sound. None guarantees that a referring clinician changes what they do.

The critical failure point sits at a boundary the laboratory controls: the format in which a result leaves the laboratory, and whether it carries enough structure, versioning, and supporting context for the receiving system to use it.

A narrative PDF may be appropriate as a human-readable clinical report. It is not, by itself, a dependable clinical-data contract. It does not reliably expose discrete, versioned fields that a receiving EHR workflow or CDS service can consistently evaluate without document extraction, NLP, custom parsing, or manual review.

A structured result does not solve the health system’s clinical workflow problem on its own. It does give the receiving system a reliable starting point: a discrete result, a patient identity, an assessment date, a model version, an intended-use statement, an applicable status, and enough evidence or provenance to understand what the result means.

The referring health system remains responsible for patient-specific clinical decisions, local care pathways, clinician-facing trigger rules, and follow-up operations. The laboratory’s responsibility is different but essential: deliver a result that is sufficiently structured, versioned, evidenced, and interoperable for the receiving system to use safely.

Preparing Computable Genetic Risk Results for Clinical Decision Support

A FHIR RiskAssessment represents likely outcomes for a patient or other subject and the likelihood of each outcome. In a genomic-risk workflow, it can carry a risk assessment alongside its status, basis, mitigation and supporting metadata.

A laboratory should avoid reducing that record to a percentile in narrative text. A machine-readable risk result may need to include:

  • The patient and ordering or referring context.
  • The condition or outcome being assessed.
  • The risk category, score, probability, percentile, or other approved output.
  • The model identifier, version, calculation date, and status.
  • The intended population and intended use.
  • Input data quality or completeness information where relevant.
  • The result’s relationship to conventional risk factors or other clinical data, where applicable.
  • Relevant model limitations, calibration considerations, and interpretation boundaries.
  • The laboratory’s review, release, and reporting status.

The final resource design should match the health system’s EHR capabilities, governing implementation guides, and workflow architecture. Risk Assessment is not the only valid representation. An implementation may use Observation, DiagnosticReport, other FHIR resources, or a combination of structured artifacts.

The requirement is not a single resource type. It is a dependable result contract that survives the trip from the laboratory system to the provider workflow.

How CDS Hooks and SMART on FHIR Support Genetic Risk Workflows

The current stable CDS Hooks 2.0.1 specification supports RESTful, workflow-triggered interactions between a CDS client, such as an EHR, and a CDS service. At a supported workflow point, such as patient-view, the client sends hook-specific context. It may also provide prefetched FHIR data, authorized access to its FHIR server, or both. The service returns a cards array, which may be empty; cards can contain information, suggested actions, and links, including links that launch a SMART app. The client controls how the response is presented and handled.

The current SMART App Launch 2.2.0 framework supports a clinician-facing application that launches with authorized patient and user context. That application can bring together the risk explanation, model metadata, relevant clinical context, and approved pathway options when a brief EHR prompt is not enough.

Neither standard turns a PDF into dependable decision-support data. A receiving organization may extract information from documents through custom parsing, NLP, or manual review, but that introduces variability, delay, and implementation burden. Structured, versioned delivery gives the EHR and CDS service a more reliable basis for evaluation.

Variant Evidence Management Must Support Risk Result Versioning

A risk result without version and evidence history is difficult to reassess, explain, or update.

For monogenic and hybrid risk models, a change in an underlying clinical variant interpretation may affect an earlier risk conclusion. The ACMG points to consider on reevaluation and reanalysis provide guidance on laboratory policies for variant reevaluation, case-level reanalysis, and communication of relevant classification changes. The laboratory needs to know which issued results used that assertion, which reports and receiving providers may be affected, and which cases require review under the laboratory’s approved reclassification policy.

For polygenic scores, reassessment is usually driven by different events: a new model version, updated calibration, changes to the intended population, input-data quality findings, revised validation evidence, or a change in the laboratory’s reporting policy. The model may not depend on a single pathogenicity assertion, but the laboratory still needs to preserve which model and rule set produced each result.

This is why variant evidence management and risk-result management belong in the same delivery architecture. The laboratory needs to preserve the distinction between:

  • The evidence and interpretation supporting a monogenic finding.
  • The model, version, calibration, and inputs supporting a polygenic score.
  • The combined policy used to generate a hybrid-risk result.
  • The report and structured data payload issued to the referring provider.
  • The later events that may trigger reassessment, amendment, or notification.

A laboratory cannot responsibly tell a referring provider that a result remains current unless it can reconstruct how that result was produced and determine whether the relevant evidence or model state has changed.

Provider Feedback Requires a Separate Agreement and Integration

A dismissed intervention can mean alert fatigue, existing specialty care, a workflow mismatch, or a clinically appropriate decision to wait. Dismissal alone does not establish which explanation applies or whether care occurred through another route.

These decisions occur in the referring provider’s workflow. Sending a structured risk result does not create a standard EHR-to-reference-laboratory channel for returning deferral reasons.

CDS Hooks 2.0.1 defines an optional feedback endpoint through which a CDS client can report accepted or overridden guidance to the CDS service. An override reason is optional. This is feedback to the CDS service, not an automatic return message to the laboratory that supplied the underlying risk result. It also does not, by itself, establish that a clinical action was completed.

If the laboratory operates the CDS service, supported feedback may be available within that agreed implementation. If it does not, any sharing of provider-side actions or deferral reasons with the laboratory requires a separate arrangement and supported integration.

Where both organizations agree that such feedback is useful and permitted, the implementation should define:

  • Which events are recorded and what they mean.
  • Which organization receives them and under what permissions.
  • How patient, result, result-version, and CDS interaction identifiers are associated.
  • Which interface or reporting mechanism carries the information.
  • How missing, incomplete, or unavailable feedback is represented.

Discrete result identifiers can support that association. They do not create the return channel or authorize the disclosure.

The categories below are possible locally agreed records. They are not a standard vocabulary or information that an EHR automatically sends to a reference laboratory.

Locally recorded stateWhat it may indicatePotential use if feedback is shared
Patient already under specialty careExisting care or a potentially redundant notification; context is needed before changing suppression logicLaboratory and referring provider, if shared
Required clinical context missingA data gap in the receiving workflow, referral information, or source resultLaboratory and referring provider, if shared
Patient outside model’s intended populationA model-applicability boundaryLaboratory, model governance, and provider, if shared
Patient declined actionPatient preference, not necessarily a workflow failureReferring provider and care team
Recommended action already completedA timing or notification issueLaboratory and referring provider, if shared
Clinician selected another pathwayPatient-specific judgment or local-policy variationReferring provider; possible aggregate learning if shared

This is a two-sided handoff. The laboratory should not claim to own clinician action or assume that provider-side feedback will be available.

Where feedback is not shared, the laboratory can still evaluate its own result quality, version history, and delivery performance. It should not infer clinician action, patient refusal, or workflow failure from the absence of a return message.

Model Governance Starts in the Laboratory

A referring clinician should not have to treat a risk category as a black box.

HTI-1 adopted the decision-support-intervention certification criterion at 45 CFR 170.315(b)(11). For predictive decision support interventions supplied as part of certified health IT, the rule establishes source-attribute transparency and ongoing risk-management requirements. It defines predictive DSI as technology using algorithms or models derived from training or example data to produce outputs such as predictions, classifications, recommendations, evaluations, or analyses.

The ONC HTI-1 Decision Support Interventions fact sheet identifies 31 source attributes for applicable predictive DSIs, including intended use, intended users and patients, cautioned out-of-scope use, input data, fairness, external validation, performance, maintenance, and update or continued-validation schedules.

A laboratory risk program does not automatically fall within every certification obligation simply because it produces a score. Qualified legal, regulatory, clinical, and product leaders must determine the requirements applicable to a particular implementation.

The operating lesson applies before a health system asks about certification. A laboratory issuing genomic risk results should govern the intended use, model version, input data, population applicability, validation evidence, update schedule, known limitations, reporting policy, and reassessment process.

Waiting for a customer to demand this evidence places the laboratory in a weaker position than maintaining it as part of the risk-result product from the beginning.

What NonStop Engineers for Genetic Risk Clinical Decision Support

A technically accurate genetic risk score can be an input to decision support. Structured, versioned delivery makes it easier for a receiving system to evaluate that input alongside clinical context and locally governed decision logic. It does not turn the laboratory result into a complete CDS intervention or guarantee clinician action.

NonStop engineers that handoff on the laboratory side.

  • Variant interpretation workflow and structured result preparation support tertiary analysis, clinical interpretation workflows, review queues, evidence assembly, and controlled movement of approved findings into reporting. Varion is designed to work with a shared GA4GH VRS knowledge layer and the broader interoperability stack.
  • Versioned evidence and reclassification tracking turns laboratory classifications into an owned, versioned, queryable knowledge base on a GA4GH VRS store, with ClinVar difference monitoring that can surface potential review candidates. GENVAR supports this knowledge and monitoring layer.
  • EHR order and result interoperability validates order data, supports reconciliation and exception handling, and synchronizes FHIR R4 and HL7 workflows between referring-provider EHRs and laboratory systems. Intergenix provides the integration and validation layer for these workflows.
  • Clinical reporting engineering connects approved interpretation output to governed report templates, structured result fields, sign-out workflows, amendments, and delivery requirements. The implementation can reduce manual transcription points while preserving the laboratory-controlled reporting policy.
  • FHIR clinical-data engineering designs versioned risk-result structures, API contracts, patient and result-identity mappings, model metadata, provenance records, and delivery patterns suitable for receiving EHR and CDS workflows.
  • Data engineering and operational analytics establish the data layer for model lifecycle management, result traceability, reclassification impact analysis, delivery monitoring, and optional provider-feedback integrations where separately agreed and supported.
  • Forward-deployed engineering works with laboratory directors, medical directors, clinical informatics, bioinformatics, reporting, and client-implementation teams to map the current result lifecycle, build the missing controls, and transfer durable ownership of the platform and workflow to the laboratory.

The result should not be a risk score trapped in a PDF, a portal, or a disconnected report interface.

It should be a versioned clinical data product that can be incorporated into a receiving provider’s clinical workflow without losing meaning, evidence, or traceability. Patient-specific decisions and actions remain with the receiving clinical team.

Five Questions for a Lab Evaluating Its Genetic Risk Result Handoff

Before investing in a new interpretation platform, a new scoring model, or another provider portal, a laboratory should ask:

  1. Does the risk result leave the laboratory as structured data, or only as narrative content and a document attachment?
  2. If an underlying variant interpretation, model version, calibration, or reporting policy changes, can the laboratory identify every issued result that may require review?
  3. Does the reporting workflow map approved interpretation and model output into structured result fields, or does it depend on manual re-entry and disconnected documents?
  4. Can the laboratory show a referring provider why a patient met a risk threshold, including the applicable model, date, intended use, and relevant limitations?
  5. Have the laboratory and receiving organization agreed whether provider-side feedback will be shared, what it means, and which supported channel and permissions would enable it?

If the answers reveal missing structured data, version history, or result traceability, the laboratory has an infrastructure gap to address. Provider-side feedback is a separate joint design choice, not an automatic feature or prerequisite of laboratory result delivery.

Ready to Engineer the Risk-to-Action Handoff?

NonStop’s Architecture Review maps the risk-result lifecycle from interpretation and evidence versioning through structured reporting, FHIR delivery, and EHR interoperability. It identifies where the handoff to referring providers is breaking down and what must change for results to become usable downstream clinical data.

Genetic Risk Clinical Decision Support FAQs

What is genetic risk clinical decision support?

Genetic risk clinical decision support uses genomic risk information, relevant patient context, and clinical logic to support a clinician’s assessment or choice of action. A laboratory’s result can supply an important input. Structured data, model metadata, version history, and appropriate provenance support reliable reuse, but they do not independently create a complete CDS intervention or guarantee action.

Why is a PDF genetic risk report difficult to reuse in automated CDS?

A PDF is optimized for human reading and can support a clinician’s assessment. It may not expose the model version, risk category, result date, intended-use context, evidence status, or structured fields that an automated EHR workflow needs. A health system can extract content through custom parsing, natural-language processing, or manual work, but that creates additional variability and implementation burden. Structured delivery gives downstream workflows a more dependable basis for evaluation.

What is FHIR RiskAssessment used for in genomic risk stratification?

A FHIR RiskAssessment represents likely outcomes for a patient or other subject and the likelihood of each outcome. In genomic risk stratification, it can carry a result with relevant model metadata, status, basis, mitigation information and result date. It is one possible FHIR representation; the final resource design should match the receiving health system’s EHR capabilities, implementation guides, and governance model.

How do CDS Hooks and SMART on FHIR support genetic risk delivery?
CDS Hooks 2.0.1 allows a CDS client, such as an EHR, to invoke a CDS service at supported workflow points. Requests include hook-specific context and may include prefetched FHIR data, authorized FHIR access, or both. The service returns cards that can contain information, suggestions, and links, including SMART app links. SMART App Launch 2.2.0 supports authorized app access and launch context for deeper review.

These standards do not automatically structure a laboratory document or ingest a risk result into the EHR. The agreed data integration must make the needed result and clinical context available to the service or app.

Why does variant reclassification matter for a genetic risk result over time?

For monogenic and hybrid risk models, a revised variant interpretation may affect an earlier risk conclusion and may require review under the laboratory’s approved policy. The ACMG points to consider on reevaluation and reanalysis support defined laboratory policies for reviewing and communicating relevant changes. For polygenic scores, reassessment is more commonly triggered by changes to the model version, calibration, intended population, input data quality, validation evidence, or reporting policy. Both situations require versioned result records and clear reassessment rules.